Friedrich Metzger

Advisor at Skyhawk Therapeutics

Prof. Metzger is a leading scientist in RNA-based disease and neurological conditions. As project leader and Head of Discovery Rare Diseases at Roche for 15 years, he ran drug discovery programs for Alzheimer’s, ALS, Parkinson’s, Duchenne Muscular Dystrophy (DMD) & Spinal Muscular Atrophy (SMA). Prof. Metzger scientifically supervised Roche’s SMA splicing modifier program, currently in pivotal clinical trials, and championed two publications describing its molecular mechanism, in Nature in 2017 and Science, in 2014. He currently serves as Professor in Neurobiology at the University of Freiburg, Germany. He received a Ph.D. in Pharmacology at University of Tübingen, Germany.

Timeline

  • Advisor

    Current role